Proceeds support advancement of two next-generation precision oncology programs into clinical development within 12 monthsFinancing led by Goldman Sachs Alternatives with participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and existing investorsSAN DI...

Related Keywords

Josh Richardson , Uwe Schoenbeck , Eric Murphy , Linkedin , Alterome Therapeutics Inc , Twitter , Life Sciences Investing At Goldman Sachs Alternatives , Goldman Sachs , Goldman Sachs Alternatives , Canaan Partners , Driehaus Capital Management , Digitalis Ventures , Blue Owl Capital , Alterome Therapeutics , Nextech Invest , Vida Ventures , Boxer Capital , Managing Director , Life Sciences Investing ,